-
1
-
-
0032437869
-
Paclitaxel in breast cancer
-
Perez EA: Paclitaxel in breast cancer. Oncologist 3:373-389, 1998
-
(1998)
Oncologist
, vol.3
, pp. 373-389
-
-
Perez, E.A.1
-
2
-
-
0037445132
-
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
-
Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
-
(2003)
J Clin Oncol
, vol.21
, pp. 976-983
-
-
Henderson, I.C.1
Berry, D.A.2
Demetri, G.D.3
-
3
-
-
0035752985
-
Side effects of chemotherapy and combined chemo-hormonal therapy in women with early-stage breast cancer
-
Partridge AH, Burstein HJ, Winer EP: Side effects of chemotherapy and combined chemo-hormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 30:135-142, 2001
-
(2001)
J Natl Cancer Inst Monogr
, vol.30
, pp. 135-142
-
-
Partridge, A.H.1
Burstein, H.J.2
Winer, E.P.3
-
4
-
-
0021878134
-
Early and delayed clinical cardiotoxicity of doxorubicin
-
Buzdar AU, Marcus C, Smith TL, et al: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55:2761-2765, 1985
-
(1985)
Cancer
, vol.55
, pp. 2761-2765
-
-
Buzdar, A.U.1
Marcus, C.2
Smith, T.L.3
-
5
-
-
0041883701
-
Cardiotoxic effects of anthracycline-taxane combinations
-
Perotti A, Cresta S, Grasselli G, et al: Cardiotoxic effects of anthracycline-taxane combinations. Expert Opin Drug Saf 2:59-71, 2003
-
(2003)
Expert Opin Drug Saf
, vol.2
, pp. 59-71
-
-
Perotti, A.1
Cresta, S.2
Grasselli, G.3
-
6
-
-
0036498781
-
Cardiac dysfunction in the trastuzumab clinical trials experience
-
Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
-
(2002)
J Clin Oncol
, vol.20
, pp. 1215-1221
-
-
Seidman, A.1
Hudis, C.2
Pierri, M.K.3
-
7
-
-
0036784463
-
Trastuzumab-associated cardiotoxicity
-
Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 95:1592-1600, 2002
-
(2002)
Cancer
, vol.95
, pp. 1592-1600
-
-
Keefe, D.L.1
-
8
-
-
0034872172
-
Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer
-
Gianni L, Dombernowsky P, Sledge G, et al: Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer. Ann Oncol 12:S63-S68, 2001 (suppl 1)
-
(2001)
Ann Oncol
, vol.12
, Issue.SUPPL. 1
-
-
Gianni, L.1
Dombernowsky, P.2
Sledge, G.3
-
9
-
-
0011715451
-
First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease
-
abstr 132
-
Gianni L, Baselga J, Eiermann W, et al: First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 132)
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Gianni, L.1
Baselga, J.2
Eiermann, W.3
-
10
-
-
0035890811
-
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer
-
Perez EA, Vogel CL, Irwin DH, et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-1223, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 4216-11223
-
-
Perez, E.A.1
Vogel, C.L.2
Irwin, D.H.3
-
11
-
-
0035873815
-
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
-
Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 2587-2595
-
-
Seidman, A.D.1
Fornier, M.N.2
Esteva, F.J.3
-
12
-
-
0001136449
-
Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial
-
abstr 129
-
Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial. Proc Am Soc Clin Oncol 20:33a, 2001 (abstr 129)
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Green, M.C.1
Buzdar, A.U.2
Smith, T.3
-
13
-
-
21844480293
-
CALGB 9840: Phase 111 study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized to T in HER2 normal MBC
-
Seidman AD, Berry D, Cirrincione C, et al: CALGB 9840: Phase 111 study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized to T in HER2 normal MBC. Proc Am Soc Clin Oncol 22:65, 2004
-
(2004)
Proc Am Soc Clin Oncol
, vol.22
, pp. 65
-
-
Seidman, A.D.1
Berry, D.2
Cirrincione, C.3
-
14
-
-
18744395754
-
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study
-
Burstein HJ, Harris LN, Gelman R, et al: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 21:46-53, 2003
-
(2003)
J Clin Oncol
, vol.21
, pp. 46-53
-
-
Burstein, H.J.1
Harris, L.N.2
Gelman, R.3
-
15
-
-
0347995045
-
Pilot trial of trastuzumab starting with or after doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER-2 positive advance breast cancer
-
Bianchi G, Albanell J, Eiermann W, et al: Pilot trial of trastuzumab starting with or after doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER-2 positive advance breast cancer. Clin Cancer Res 9:5944-5951, 2003
-
(2003)
Clin Cancer Res
, vol.9
, pp. 5944-5951
-
-
Bianchi, G.1
Albanell, J.2
Eiermann, W.3
-
16
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
17
-
-
0035152095
-
Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation
-
Zambetti M, Moliterni A, Materazzo C, et al: Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19:37-43, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 37-43
-
-
Zambetti, M.1
Moliterni, A.2
Materazzo, C.3
-
19
-
-
0141799967
-
Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival
-
Woodward WA, Strom EA, Tucker SL, et al: Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21:3244-3248, 2003
-
(2003)
J Clin Oncol
, vol.21
, pp. 3244-3248
-
-
Woodward, W.A.1
Strom, E.A.2
Tucker, S.L.3
|